LPL Financial LLC Boosts Holdings in Glaukos Corporation $GKOS

Key Points

• LPL Financial LLC raised its stake in Glaukos Corporation by 25.1% during the 1st quarter, owning 15,775 shares valued at approximately $1.55 million as reported in SEC filings.
• Recent analysis shows that Glaukos has received mixed ratings from analysts, with target prices ranging from $72.00 to $176.00 and an average rating of 'Moderate Buy'.
• Glaukos Corporation reported $124.12 million in revenue for the last quarter, outperforming analyst expectations, and indicated an optimistic forecast despite a negative EPS of ($0.24).

LPL Financial LLC grew its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 25.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,775 shares of the medical instruments supplier's stock after acquiring an additional 3,163 shares during the quarter. LPL Financial LLC's holdings in Glaukos were worth $1,553,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bessemer Group Inc. grew its stake in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 158 shares in the last quarter. Whipplewood Advisors LLC lifted its stake in shares of Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 277 shares during the period. First Horizon Advisors Inc. lifted its stake in Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 159 shares during the period. Versant Capital Management Inc increased its holdings in shares of Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 327 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its position in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GKOS has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price target on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Needham & Company LLC dropped their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. UBS Group raised their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. William Blair upgraded Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, BTIG Research reissued a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $127.42.

Glaukos Trading Up 1.6%

GKOS traded up $1.49 during mid-day trading on Tuesday, reaching $93.04. The stock had a trading volume of 156,913 shares, compared to its average volume of 945,459. The stock has a market capitalization of $5.34 billion, a P/E ratio of -56.47 and a beta of 0.78. The firm's fifty day simple moving average is $96.09 and its two-hundred day simple moving average is $100.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 52 week low of $77.10 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company's revenue was up 29.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.